WANY
CRNX icon

Wealthspire Advisors (New York)’s Crinetics Pharmaceuticals CRNX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40
Closed -$1.67K – 1432
2025
Q3 		$1.67K Buy
+40
New +$1.28K ﹤0.01% 2657

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wealthspire Advisors (New York)'s CRNX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 40 shares — an estimated $1.67K sold.

Wealthspire Advisors (New York) first reported a position in CRNX in Q3 2025 and held it in 1 quarter. The position peaked at $1.67K in Q3 2025. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 40 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $1.67K.
  • Wealthspire Advisors (New York) first reported a position in Crinetics Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Crinetics Pharmaceuticals position peaked at $1.67K in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.